Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

PubWeight™: 2.42‹?› | Rank: Top 2%

🔗 View Article (PMC 3624083)

Published in Gastroenterology on January 04, 2013


Daniela Sia1, Yujin Hoshida, Augusto Villanueva, Sasan Roayaie, Joana Ferrer, Barbara Tabak, Judit Peix, Manel Sole, Victoria Tovar, Clara Alsinet, Helena Cornella, Brandy Klotzle, Jian-Bing Fan, Christian Cotsoglou, Swan N Thung, Josep Fuster, Samuel Waxman, Juan Carlos Garcia-Valdecasas, Jordi Bruix, Myron E Schwartz, Rameen Beroukhim, Vincenzo Mazzaferro, Josep M Llovet

Author Affiliations

1: Barcelona-Clínic Liver Cancer Group (HCC Translational Research Laboratory, Liver Unit, Pathology Department), Institut d'Investigacions Biomèdiques August Pi I Sunyer, Liver Unit, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.

Articles citing this

Cholangiocarcinoma. Lancet (2014) 4.52

Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology (2013) 2.81

Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature (2014) 2.77

Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. Hepatology (2013) 2.42

New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist (2014) 1.61

Unique genomic profile of fibrolamellar hepatocellular carcinoma. Gastroenterology (2014) 1.59

IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism. Hepatology (2015) 1.52

Immunohistochemical Typing of Adenocarcinomas of the Pancreatobiliary System Improves Diagnosis and Prognostic Stratification. PLoS One (2016) 1.38

Cholangiocarcinoma: molecular pathways and therapeutic opportunities. Semin Liver Dis (2014) 1.28

Generation of functional cholangiocyte-like cells from human pluripotent stem cells and HepaRG cells. Hepatology (2014) 1.09

Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets. Ann Surg Oncol (2014) 1.02

Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies. Oncotarget (2015) 1.02

Transcriptome profiling of archived sectioned formalin-fixed paraffin-embedded (AS-FFPE) tissue for disease classification. PLoS One (2014) 1.01

Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol (2016) 0.96

Intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am (2014) 0.95

Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine. Ecancermedicalscience (2014) 0.95

The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome. Hum Pathol (2013) 0.92

New insights into the molecular pathogenesis of intrahepatic cholangiocarcinoma. J Gastroenterol (2013) 0.92

Functional and genetic deconstruction of the cellular origin in liver cancer. Nat Rev Cancer (2015) 0.92

CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice. Proc Natl Acad Sci U S A (2015) 0.89

Cholangiocarcinoma: Current Knowledge and New Developments. Gut Liver (2016) 0.89

Tissue Microbiome Profiling Identifies an Enrichment of Specific Enteric Bacteria in Opisthorchis viverrini Associated Cholangiocarcinoma. EBioMedicine (2016) 0.87

The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets. Oncotarget (2016) 0.87

Genome-wide single nucleotide polymorphism array analysis reveals recurrent genomic alterations associated with histopathologic features in intrahepatic cholangiocarcinoma. Int J Clin Exp Pathol (2014) 0.87

Patterns of chromosomal copy-number alterations in intrahepatic cholangiocarcinoma. BMC Cancer (2015) 0.87

Molecular genetics and targeted therapeutics in biliary tract carcinoma. World J Gastroenterol (2016) 0.86

Molecular pathogenesis of cholangiocarcinoma. Dig Dis (2014) 0.83

Clinical significance of nerve growth factor and tropomyosin-receptor-kinase signaling pathway in intrahepatic cholangiocarcinoma. World J Gastroenterol (2014) 0.81

A perspective on molecular therapy in cholangiocarcinoma: present status and future directions. Hepat Oncol (2014) 0.81

Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives. ISRN Hepatol (2014) 0.81

Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing. Exp Mol Pathol (2015) 0.79

Molecular diagnosis of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci (2014) 0.79

Emerging Molecular Therapeutic Targets for Cholangiocarcinoma. J Hepatol (2017) 0.78

Intratumoral heterogeneity of intrahepatic cholangiocarcinoma. Oncotarget (2017) 0.78

Clinical and biological significance of precursor lesions of intrahepatic cholangiocarcinoma. World J Hepatol (2015) 0.77

LTβR signalling preferentially accelerates oncogenic AKT-initiated liver tumours. Gut (2015) 0.77

IDH mutations in liver cell plasticity and biliary cancer. Cell Cycle (2014) 0.77

Co‑expression of the carbamoyl‑phosphate synthase 1 gene and its long non‑coding RNA correlates with poor prognosis of patients with intrahepatic cholangiocarcinoma. Mol Med Rep (2015) 0.77

Recurrent Amplification at 13q34 Targets at CUL4A, IRS2, and TFDP1 As an Independent Adverse Prognosticator in Intrahepatic Cholangiocarcinoma. PLoS One (2015) 0.77

The Prognostic Role of SOCS3 and A20 in Human Cholangiocarcinoma. PLoS One (2015) 0.76

Novel therapeutic strategy targeting the Hedgehog signalling and mTOR pathways in biliary tract cancer. Br J Cancer (2015) 0.76

Genomic decoding of intrahepatic cholangiocarcinoma reveals therapeutic opportunities. Gastroenterology (2013) 0.76

Integrative analysis of transcriptional regulatory network and copy number variation in intrahepatic cholangiocarcinoma. PLoS One (2014) 0.76

Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma. Cancer Cell (2017) 0.75

Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications. Oncotarget (2016) 0.75

Biliary tract cancers: SEOM clinical guidelines. Clin Transl Oncol (2015) 0.75

Intrahepatic cholangiocarcinoma: current perspectives. Onco Targets Ther (2017) 0.75

Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1. J Hematol Oncol (2017) 0.75

Liver cancer oncogenomics: opportunities and dilemmas for clinical applications. Hepat Oncol (2015) 0.75

Targeting Angiogenesis in Biliary Tract Cancers: An Open Option. Int J Mol Sci (2017) 0.75

Two classes of intrahepatic cholangiocarcinoma defined by relative abundance of mutations and copy number alterations. Oncotarget (2016) 0.75

Building a staircase to precision medicine for biliary tract cancer. Nat Genet (2015) 0.75

An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma. Int J Genomics (2015) 0.75

Genetic profiling of intrahepatic cholangiocarcinoma and its clinical implication in targeted therapy. Am J Cancer Res (2016) 0.75

Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer. Sci Rep (2016) 0.75

Hippo Signaling in the Liver Regulates Organ Size, Cell Fate, and Carcinogenesis. Gastroenterology (2016) 0.75

Rac1-Mediated DNA Damage and Inflammation Promote Nf2 Tumorigenesis but Also Limit Cell-Cycle Progression. Dev Cell (2016) 0.75

Liver Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. Cancers (Basel) (2017) 0.75

A New Preoperative Prognostic System Combining CRP and CA199 For Patients with Intrahepatic Cholangiocarcinoma. Clin Transl Gastroenterol (2017) 0.75

Articles cited by this

Mutations of the BRAF gene in human cancer. Nature (2002) 65.42

Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 37.09

Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57

Stat3 as an oncogene. Cell (1999) 17.39

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med (2010) 15.71

Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci U S A (2004) 10.47

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med (2010) 8.77

Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (2004) 6.98

Cholangiocarcinoma. Lancet (2005) 6.01

IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med (2009) 5.05

Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci U S A (2010) 4.95

Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology (2007) 4.73

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35

Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology (2008) 3.95

Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77

Cancer genomics: from discovery science to personalized medicine. Nat Med (2011) 3.66

The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci U S A (2010) 3.18

Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol (2002) 2.70

Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene (2006) 2.65

Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology (2011) 2.63

Cholangiocarcinoma. Clin Liver Dis (2008) 2.33

B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A (2006) 2.24

Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol (2011) 2.13

Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut (2000) 1.89

A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer (2010) 1.87

Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. Cancer Res (2010) 1.82

Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res (2006) 1.80

Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology (2005) 1.78

Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol (2010) 1.69

Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology (2006) 1.68

Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology (2012) 1.57

Early accelerated approval for highly targeted cancer drugs. N Engl J Med (2011) 1.55

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer (2009) 1.54

Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis. Cancer Res (2011) 1.52

Intrahepatic cholangiocarcinoma: new insights in pathology. Semin Liver Dis (2011) 1.46

Comparison of gene expression profiles between Opisthorchis viverrini and non-Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma. Hepatology (2006) 1.40

Surgical management of intrahepatic cholangiocarcinoma--a population-based study. Ann Surg Oncol (2007) 1.39

Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. Hum Pathol (1998) 1.29

Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma. Mod Pathol (2005) 1.26

B7-h4 expression in human melanoma: its association with patients' survival and antitumor immune response. Clin Cancer Res (2011) 1.17

Genome wide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract. J Exp Clin Cancer Res (2009) 1.12

Advances in the diagnosis, evaluation and management of cholangiocarcinoma. Curr Opin Gastroenterol (2006) 1.07

c-erbB-2 protein is expressed in hepatolithiasis and cholangiocarcinoma. Histopathology (1998) 1.06

Identification of intrahepatic cholangiocarcinoma related genes by comparison with normal liver tissues using expressed sequence tags. Biochem Biophys Res Commun (2006) 1.01

Microsatellite instability and alternative genetic pathway in intrahepatic cholangiocarcinoma. J Hepatol (2001) 1.01

A detailed transcriptional map of the chromosome 12p12 tumour suppressor locus. Eur J Hum Genet (2002) 0.91

Clinical significance of cell cycle- and apoptosis-related markers in biliary tract cancer: a tissue microarray-based approach revealing a distinctive immunophenotype for intrahepatic and extrahepatic cholangiocarcinomas. Am J Clin Pathol (2008) 0.88

Copy number and loss of heterozygosity detected by SNP array of formalin-fixed tissues using whole-genome amplification. PLoS One (2011) 0.85

Transcriptional profiling of human microvascular endothelial cells in the proliferative and quiescent state using cDNA arrays. Angiogenesis (1999) 0.84

Articles by these authors

A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39

Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30

Hepatocellular carcinoma. Lancet (2003) 22.54

Hepatocellular carcinoma. Lancet (2012) 18.09

Genome-wide detection and characterization of positive selection in human populations. Nature (2007) 17.27

Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28

High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68

Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet (2002) 12.16

The somatic genomic landscape of glioblastoma. Cell (2013) 11.73

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology (2003) 11.55

Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27

Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87

High density DNA methylation array with single CpG site resolution. Genomics (2011) 10.35

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis (2010) 9.73

GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol (2011) 9.60

Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41

Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20

High-throughput DNA methylation profiling using universal bead arrays. Genome Res (2006) 8.05

Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76

Pan-cancer patterns of somatic copy number alteration. Nat Genet (2013) 7.73

TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61

SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48

Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45

Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09

Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93

Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology (2002) 6.92

Characterization of the single-cell transcriptional landscape by highly multiplex RNA-seq. Genome Res (2011) 6.90

Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet (2011) 6.89

Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology (2008) 6.75

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 6.39

Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35

Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10

Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95

Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93

Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis (2010) 5.85

Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther (2008) 5.78

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71

The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33

Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol (2008) 5.24

Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol (2006) 5.17

Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest (2009) 5.07

Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology (2013) 5.05

Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology (2002) 4.83

Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med (2006) 4.63

SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature (2011) 4.57

Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis (2005) 4.51

Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50

Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet (2013) 4.48

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35

Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins. Nature (2012) 4.35

Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study. J Hepatol (2013) 4.28

miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A (2009) 4.15

Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13

Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03

Profiling alternative splicing on fiber-optic arrays. Nat Biotechnol (2002) 3.94

Differential allelic expression in the human genome: a robust approach to identify genetic and epigenetic cis-acting mechanisms regulating gene expression. PLoS Genet (2008) 3.92

Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology (2007) 3.85